Successful opacification of the left heart chambers on echocardiographic examination after intravenous injection of a new saccharide based contrast agent.
A new monosaccharide microparticle based echocardiographic contrast agent (SH U 508) was injected intravenously into five healthy male volunteers following which the heart was imaged in an apical four-chamber view.  Volumes of 2, 4, 8, and 16 mL of SH U 508 were incrementally injected into each volunteer.  Concentrations of  50, 100, 200, 300, and 400 mg microparticles per mL of suspension were used in five successive examinations.  Left heart opacification of diagnostic value was obtained during the whole cardiac cycle with concentrations of 300 and 400 mg/mL.  There was no interference in imaging of the left ventricular walls due to increased attenuation.  SH U 508 showed a good tolerance.  No side effect was observed and no clinical relevant changes were observed in the heart rate, blood pressure, ECG, blood chemistry, hematology or urinalysis findings.  This new agent may greatly extend the role of cardiac ultrasound and may also permit the examination of the arterial circulation in other organs.
Schlief
R
R
Departments of Clinical Research Diagnostics and Human Pharmacology, Schering AG Berlin/Bergkamen, Federal Republic of Germany.
Staks
T
T
Mahler
M
M
Rufer
M
M
Fritzsch
T
T
Seifert
W
W
D000328:Adult; D016279:Atrial Function, Left / Q000502:physiology*; D003287:Contrast Media; D004341:Drug Evaluation; D004452:Echocardiography / Q000379:methods*; D005690:Galactose; D006801:Humans; D008297:Male; D016277:Ventricular Function, Left / Q000502:physiology*